We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Treatment outcome of maxillary sinus cancer.
- Authors
Hye Sung Won; Sang Hoon Chun; Bum-soo Kim; So Ryoung Chung; Ie Ryung Yoo; Chan-Kwon Jung; Yeon-Sil Kim; Dong-il Sun; Min Sik Kim; Jin-Hyoung Kang
- Abstract
The standard treatment in the early stage of maxillary sinus cancer is surgical resection followed by postoperative radiation therapy. However, for locally advanced maxillary sinus cancer, a multimodality treatment approach is strongly recommended to improve the survival rate and quality of life of the patient. We determined the treatment outcomes of induction chemotherapy, concurrent chemoradiation therapy, and surgical resection for locally advanced maxillary sinus cancer. Forty-four patients with locally advanced maxillary sinus cancer, who had been treated between January 1990 and April 2008 at Kangnam St. Mary's Hospital, were retrospectively analyzed. The objective response rates were 70%, 53%, and 57% in the intra-arterial induction chemotherapy, intravenous induction chemotherapy, and concurrent chemoradiation therapy groups, respectively. The orbital preservation rates were 83%, 100%, and 75% in the intra-arterial induction chemotherapy, intravenous induction chemotherapy, and surgical resection groups, respectively. In seven of nine patients in whom the orbit could be preserved after induction chemotherapy, the primary tumors were removed completely. However, although the orbits were preserved in three patients who underwent surgical resection as a primary treatment, all three cases were confirmed to be incomplete resections. We found that active induction chemotherapy for locally advanced cancer of the maxillary sinus increased the possibility of complete resection with orbital preservation as well as tumor down-staging.
- Subjects
SURGICAL excision; DRUG therapy; RADIOTHERAPY; QUALITY of life; MAXILLARY sinus cancer; PRESERVATION of organs, tissues, etc.; CANCER patients; CLINICAL trials; HOSPITALS; CANCER treatment
- Publication
Rare Tumors, 2009, Vol 1, p110
- ISSN
2036-3605
- Publication type
Article
- DOI
10.4081/rt.2009.e36